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 Th e prevalence of chronic kidney disease 
(CKD) is a global, growing health prob-
lem. In the United States, more than 
10 % of the population older than 20 years 
have CKD. The treatment options are 
limited and largely unsuccessful for the 
long-term management of the disease. 
End-stage renal failure and cardiovascular 
complications are the prevalent causes of 
morbidity and mortality. Understanding 
the mechanisms underlying disease onset 
and progression is therefore imperative for 
fi nding better therapeutic approaches. 
 Endothelial dysfunction was positively 
associated with both CKD and cardiovas-
cular disease; however, a causative role was 
only partly documented. Reduced nitric 
oxide (NO) production in patients and 
animal models of CKD was also found, 
concurrently with endothelial dysfunc-
tion. Asymmetric  N G , N G -dimethyl-
arginine (ADMA), an endogenous 
methylated arginine analog, results from 
protein turnover, and its metabolism 
is facilitated by dimethylarginine dimethy-
laminohydrolases (DDAH-1 and -2 iso-
forms). ADMA inhibits nitric oxide 
synthases (NOSs), which may in part 
explain the impaired vasorelaxation, ele-
vated infl ammation, and reduced angio-
genesis reported in patients and animal 
models of CKD 1 ( Figure 1 ). Several epide-
miological studies documented an increase 
in ADMA in patients with CKD and have 
identifi ed ADMA as an independent pre-
dictor of the severity of the disease as well 
as the associated cardiovascular complica-
tions. 2 For example, Zoccali  et al. have 
identifi ed plasma concentration of ADMA 
as the second strongest predictor of mor-
tality and cardiovascular disease in patients 
with chronic renal failure. 2 An inverse 
relationship between glomerular fi ltration 
rate and plasma concentration of ADMA 
is apparent in patients with cardio vascular 
disease and has been implicated in their 
increased cardiovascular risk. Importantly, 
the elevated ADMA and reduced NO pro-
duction can start very early in the natural 
history of CKD and can precede overt 
clinical signs of the disease such as a signi-
fi cant reduction in glomerular fi ltration 
rate. Th is raises the possibility that ADMA 
may be involved in the pathophysiological 
process rather than being solely a marker 
for kidney disease. However, clear mecha-
nistic evidence to prove that ADMA is a 
true contributor to the disease onset and / 
or progression is missing. 
 The study by Kajimoto  et al. 3 (this 
issue) brings proof-of-concept evidence 
that a rise in ADMA concentration is 
critically linked to endothelial dysfunc-
tion, albeit not to clinical markers of 
CKD, such as blood urea nitrogen and 
glomerular fi ltration rate. Importantly, 
this is demonstrated in a mild model of 
CKD and in the absence of confounding 
comorbidities, notably hypertension, 
insulin resistance, or atherosclerosis. Th e 
authors used 5 / 6 uninephectomized 
C57BL / 6 and DDAH-1 transgenic mice, 
which equally develop mild CKD within 
4 weeks following nephrectomy even in 
the face of a twofold diff erence in plasma 
ADMA. As expected, the transgenic mice 
had reduced levels of ADMA (mostly due 
to the increased metabolism) that did not 
change following nephrectomy. While the 
DDAH-1 transgenics with CKD showed 
robust vaso relaxation of the aortic rings 
in response to acetylcholine, as well as 
nitrate / nitrite levels comparable to those 
in wild-type controls, the wild-type mice 
with CKD had impaired vasodilatory 
response  in vivo and reduced levels of 
nitrate / nitrite. 
 One caveat for data interpretation is 
that the increase in DDAH-1  per se may 
be responsible for some of the observed 
vascular eff ects. 4 For example, in func-
tional studies using a DDAH-1 inhibitor 
(4124W), the latter reversed bradykinin-
induced relaxation of human saphenous 
vein, which is mediated by NO. Although 
in the paper by Kajimoto  et al. 3 there is 
no evidence that DDAH-1 does not play 
a direct role, the authors did show that 
ADMA is capable of directly inducing a 
dose-dependent eff ect on vascular reacti-
vity in aortic rings from wild-type mice. 
 A very important follow-up to this study 
would be to determine the progression of 
CKD in the DDAH-1 transgenic mice vs. 
the wild-type mice. Th e study would con-
tribute to our understanding of whether 
maintenance of adequate NO production 
and vascular function under low ADMA 
concentrations in early CKD may prevent 
or signifi cantly delay the end-stage renal 
disease and premature death. 
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 Th e model of early CKD with DDAH-1 
overexpression used by Kajimoto  et al. 3 is 
well suited to mechanistic studies to 
explain the links among ADMA, endothe-
lial NOS (eNOS) activation, and NO pro-
duction in early stages of CKD. ADMA is 
a competitive inhibitor of the NOS iso-
enzymes, in particular of eNOS and neuro-
nal NOS. In 1992, Vallance  et al. reported 
that plasma from patients with end-stage 
renal disease contains suffi  cient ADMA 
to inhibit NOS. 5 Th ey reported further 
that ADMA causes dose-dependent vaso-
constriction in rats and humans. 5 
 For a long time the ability of ADMA to 
reduce NO formation and to induce vas-
cular dysfunction was attributed solely to 
the competitive inhibition of eNOS bind-
ing to the endogenous high-affi  nity sub-
strate  l -arginine. However, short-term 
studies using  l -arginine to reverse the 
competitive inhibition exerted by ADMA 
on NOS gene rated confl icting results. Th is 
raises the possibility that ADMA may 
impair NO production by mechanisms 
independent of substrate inhibition 
( Figure 1 ). Interestingly, Kajimoto  et al. 3 
showed that CKD occurs following 
nephrectomy even in mice with low 
ADMA levels, unlikely to competitively 
inhibit eNOS binding to  l -arginine. 3 Th is 
suggests that the renal eff ects of ADMA in 
the context of reduced renal mass could 
be mediated via eNOS mechanisms diff er-
ent from substrate inhibition or via mech-
anisms independent of eNOS altogether. 
Previous reports showed that administra-
tion of  l -arginine in children with CKD 
did not reduce proteinuria and failed to 
improve endothelial function. 6 Unfortu-
nately, Kajimoto  et al. 3 did not examine 
eNOS regulation in the kidney, nor did 
they determine the eff ect of  l -arginine 
infusion on the CKD onset. 
 As opposed to the renal phenotype, 
which was independent of systemic 
ADMA and NO concentration, the vascu-
lar one was dependent on ADMA and on 
the nitrate / nitrite concentration. Impaired 
vascular relaxation was associated with 
reduced Ser1177 phosphorylation of eNOS 
in the aortas of CKD WT mice with high 
levels of ADMA but not in the DDAH-1 
CKD transgenics with 50 % lower levels of 
ADMA. Th is is the fi rst report to show that 
ADMA is negatively associated with eNOS 
Ser1177 phosphorylation in large vessels 
 in vivo and that increased ADMA catabo-
lism by DDAH-1 overexpression restores 
Ser1177 phosphorylation. Importantly, 
ADMA at concentrations similar to the 
ones in mice with CKD (1 × 10   −  6  mol / l) can 
reduce basal and vascular endothelial 
growth factor (VEGF)-stimulated eNOS 
Ser1177 phosphorylation in human umbi-
lical vein endothelial cells cultured in supra-
physiological concentrations of  l -arginine. 3 
Th is raises the possibility that additional 
mechanisms may be responsible  in vivo 
for reduced NO production in a high-
ADMA milieu, especially in situations 
when  l -arginine levels are suffi  cient to out-
compete the ADMA binding to eNOS. 
 Interestingly, ADMA seems to have an 
important role in modulating the thera-
peutic response to statin therapy to 
improve endothelium-mediated vasodila-
tion. Simvastatin is known to upregulate 
the synthesis of eNOS; however, in patients 
with high levels of ADMA, simvastatin did 
not enhance endothelial function. A com-
bination of simvastatin and oral  l -arginine 
did improve endothelial function, but 
much less than in patients with low ADMA 
concentrations. 7 It is therefore tempting to 
speculate that mechanisms other than 
substrate binding, such as activation of 
eNOS via Ser1177 phosphorylation, may 
be also responsible for the observed eff ect 
in subjects with high ADMA levels. 
 Recent evidence indicates that regulation 
of eNOS activity is increasingly complex. 8 
Both serine and threonine residues can be 
phosphorylated separately or simultane-
ously, resulting in either the stimulation 
or the inhibition of eNOS activity. 
However, one of the best-documented 
post-translational modifi cations of eNOS 
is Ser1177 phosphorylation. Th is can occur 
upon stimulation with diff erent hormones 
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 Figure 1  |  Potential mechanisms of nitric oxide reduction by increased assymetric 
 N G , N G -dimethylarginine in chronic kidney disease. Even in mild or clinically salient chronic 
kidney disease, the plasma concentration of assymetric  N G , N G -dimethylarginine (ADMA) is 
increased enough to inhibit nitric oxide (NO) production. Inhibition of endothelial nitric oxide 
synthase (eNOS) occurs via competitive inhibition of  L -arginine binding resulting in reduced 
NO production. Another potential mechanism, described in the paper by Kajimoto  et al. , 3 targets 
inhibition of eNOS Ser1177 phosphorylation, potentially preventing recruitment of eNOS to the 
plasma membrane and activation. Ser1177 phosphorylation is inhibited by ADMA in response 
to vascular endothelial growth factor (VEGF) treatment because of a reduction in activation of 
extracellular signal-regulated kinases 1 and 2 (ERK1 / 2) but not in Akt activation. Both competetive 
inhibition with  L -arginine and decreased eNOS phosphorylation can lead to lower NO production. 
In turn, NO deficiency may cause endothelial dysfunction, increased inflammation, and 
reduced angiogenesis, all potential causes of end-stage renal disease (ESRD) and cardiovascular 
comorbidities such as hypertension, atherosclerosis, and diabetes. BUN, blood urea nitrogen; 
GFR, glomerular filtration rate; PI3K, phosphatidylinositol-3  -kinase; VEGFR2, vascular endothelial 
growth factor receptor 2. 
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and growth factors, such as insulin or 
VEGF, and can be transduced via diff erent 
postreceptor signaling pathways. 8 Kajimoto 
 et al. 3 showed that treatment of human 
umbilical vein endothelial cells with ADMA 
in high- l -NAME culture conditions leads 
to a dose-dependent decrease in both basal 
and VEGF-stimulated activation of eNOS 
via Ser1177 phosphorylation. Th e pathway 
leading to Ser1177 phosphorylation of 
eNOS in response to VEGF engages the 
VEGF2 receptors insulin receptor sub-
strate-1 (IRS-1) and phosphatidylinositol-
3  -kinase (PI3K) / Akt. However, in this 
study, Akt activation induced by VEGF 
treatment was not inhibited by ADMA. 
Another pathway, documented in glomer-
ular endothelial cells by Feliers  et al. , 
involves activation of PI3K and extracellu-
lar signal-regulated kinases 1 and 2 
(ERK1 / 2); 9 and Kajimoto  et al. 3 report inhi-
bition of ERK1 / 2 activation by ADMA. 
 Although these data require substantial 
validation by molecular and pharmaco-
logical manipulation of the various kinases, 
it is tempting to speculate that ADMA may 
have a selective inhibitory rather than a 
promiscuous toxic effect on signaling 
kinases, leading to decreased eNOS activa-
tion ( Figure 1 ). Also, follow-up studies that 
comprehensively examine all of the known 
eNOS phosphorylation sites and the signal-
ing molecules engaged in response to 
diff erent agonists are critical to understand 
the potentially complex eff ects of ADMA 
on eNOS activation. For example, a prom-
ising candidate may be Ser144, which is 
phosphorylated by ERK1 / 2, resulting in an 
altered ability of eNOS to bind the prolyl 
isomerase Pin1, which in turn negatively 
impacts eNOS activity. 10 
 Understanding which signaling path ways 
leading to reduced eNOS activity are 
aff ected by ADMA may lead in the future 
to the design of better therapies to reduce 
the effects of ADMA in addition to the 
current eff orts to minimize ADMA accu-
mulation in CKD and other patho logical 
conditions. Therefore, the study by 
Kajimoto  et al. 3 is important, as it opens 
new avenues to investigate molecular 
mechanisms responsible for vascular and 
renal eff ects of ADMA via eNOS inhibition 
beyond the old rivalry between ADMA 
and  l -arginine as substrates of choice for 
catalysis by eNOS. 
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 Patients with end-stage renal disease who 
require long-term hemodialysis need a 
reliable vascular access. Th e arterio venous 
fi stula is the access of choice owing to its 
long patency rate and low complication 
profi le. 1 It is created by the direct anasto-
mosis of adjacent artery and vein. Fistulae 
 From basic anatomic 
configuration to maturation 
success 
 Evangelos  Papachristou 1 and  Roberto I.  Vazquez-Padron 2 
 The arteriovenous fistula is the preferred vascular access for 
hemodialysis patients because of its low complication rate and lower 
costs, but it still has unacceptable failure rates. Krishnamoorthy  et al. 
implicate the geometry of the fistula in the temporal and spatial 
variations occurring in two of the most important parameters of 
fistula maturation, blood flow and vessel diameter. 
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capable of maintaining a minimum blood 
fl ow rate between 450 and 500  ml / min are 
considered  ‘ mature ’ and suitable for dialy-
sis. Th e problem resides in that many fi s-
tulae fail to mature (up to 66 % at 2 years). 2 
In fact, arteriovenous fi stula failure is the 
most important cause of morbidity in the 
hemodialysis population, which is cur-
rently more than 300  000 in the United 
States alone. 3 Despite the magnitude of the 
problem, there have been no major 
advances in the field of hemodialysis 
vascular access for the past three decades, 
and only a modest increased rate of schol-
arly activity in this area has been lately 
seen. 4 Th erefore, there is still an unmet 
necessity of basic studies to assess the role 
